New ETF Book by Larry Connors - Click here to read more
As part of this agreement, Pfizer has granted NicOx the right to access and use certain proprietary Xalatan(R) (latanoprost) data.
Under the terms of the agreement, NicOx is reacquiring the full development and commercialization rights to PF-03187207 (including the right to sublicense), as well as the entire current data-package and development information. NicOx can also access and use certain proprietary Xalatan(R) development information and cross -refer to Xalatan(R) regulatory filings, which could be important for the potential future development and regulatory filing of PF-03187207.
Pfizer will also provide temporary technical support to help the transition to any further clinical program. In return, NicOx has agreed to pay Pfizer two undisclosed milestones (the first of which is linked to approval in the US, European Union, and Japan, and the second on reaching predefined sales levels), in addition to royalties on future sales.
Update on August 25, 2008:
NicOx has announced the results of a dose-ranging phase II study conducted with PF-03187207 in Japanese patients with glaucoma by Pfizer.
Update on May 6, 2008:
NicOx has announced the results of a US phase II study, conducted by Pfizer, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan(R) (latanoprost) 0.005% in patients with primary open-angle glaucoma and ocular hypertension.
Update on January 3, 2008:
NicOx announced that Pfizer has initiated a dose-ranging phase II clinical study for PF-03187207 in Japan.
Update on March 29, 2007:
NicOx has announced that additional information has been communicated by Pfizer regarding the design of the first clinical study for PF-03187207 in patients with glaucoma and ocular hypertension.
Update on March 28, 2007:
NicOx announced that Pfizer has initiated the first in a series of planned clinical trials for PF-03187207, a experimental medicine for the treatment of glaucoma. The initiation of this clinical trial follows the granting of an Investigational New Drug (IND) approval for PF-03187207 by the US Food and Drug Administration (FDA), which results in a EUR1 million milestone payment from Pfizer to NicOx.
Update on February 12, 2007:
NicOx has announced the presentation of preclinical results from its August 2004 collaboration agreement with Pfizer, which is focused on the research and development of nitric oxide-donating derivatives of latanoprost for the treatment of glaucoma.
Update on November 22, 2005:
NicOx announced that Pfizer has selected a development candidate in its collaboration with NicOx, which is focused on novel nitric oxide-donating compounds in ophthalmology.
Accordingly, Pfizer has exercised its option to acquire an exclusive worldwide license to the proprietary NicOx compounds covered by the agreement. NicOx would receive EUR2 million payment from Pfizer.
Update on July 21, 2005:
NicOx has made important progress in its research, option, development, and licensing agreement with Pfizer, which is focused on the development of nitric oxide-donating compounds in the area of ophthalmology. Several compounds have been selected for their superior activity to reference compounds in an in vivo eye disease model.
Update on March 30, 2005:
NicOx has received a payment of EUR1 million from Pfizer. The agreement granted Pfizer an option to acquire an exclusive worldwide license, covering proprietary NicOx nitric oxide-donating compounds. The compounds are currently at an early-stage of preclinical development in an undisclosed field.
Announcement (August 26, 2004):
NicOx has signed a research, option, development, and license agreement with Pfizer related to selected proprietary NicOx nitric oxide-donating compounds.
Under this agreement, NicOx grants Pfizer an option to acquire an exclusive worldwide license covering early-stage nitric oxide-donating compounds in an undisclosed field. NicOx would receive a EUR1 million in upfront payment and a further EUR1 million payment after 6 months, with an additional EUR35 million in milestone payments if the collaboration results in the successful commercial development of a product. NicOx would receive royalties in line with industry standards on sales of any successful product resulting from the research collaboration.
During the first phase of the collaboration, Pfizer and NicOx would be jointly responsible for research programmes under the supervision of a joint steering committee. NicOx would synthesize nitric oxide-donating compounds to be evaluated in a series of preclinical screening and characterization tests. Upon successful completion of the first phase of the collaboration, Pfizer would be responsible for funding the further development and future global commercialization of selected lead compounds.
Deal Type Partnership Sub-Category Development,Research and discovery,Acquisition of Rights,Commercialization Deal Status Terminated: 2009-08-06
Deal Participants
Partner 1 (Company) Pfizer, Inc. Partner 2 (Company) NicOx S.A.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
